Statement of deviation(s) or variation(s) under Reg. 32

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants, for the quarter ended on September 30, 2026 Dear Sir/Ma’am, Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, please find enclosed herewith the statement of deviation(s) or variation(s) for the quarter ended September 30, 2026 in respect of utilization of funds raised through preferential issue of 11,70,000 convertible equity warrants by the Company. We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of the funds raised through preferential issue of convertible equity warrants, for the abovementioned period, for the objects stated in the explanatory statement to the Notice of the Extra-ordinary General Meeting held on January 31, 2026. The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on October 29, 2026. This intimation is also being uploaded on the website of the Company i.e., www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Enclosure: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT, FOR THE QUARTER ENDED SEPTEMBER 30, 2026 Name of listed entity Senores Pharmaceuticals Limited Mode of Fund Raising Preferential Issue of 11,70,000 Convertible Equity Warrants each convertible into one Equity Share of face value ₹10/- (Rupees Ten only) each, at an exercise price of ₹ 812/- (Rupees Eight Hundred and Twelve only) per Warrant Date of Raising Funds March 28, 2026 Amount Raised Rs. 95,00,40,000 Report filed for Quarter ended September 30, 2026 Monitoring Agency Not Applicable Monitoring Agency Name, if applicable Not Applicable Is there a Deviation / Variation in use of No funds raised If yes, whether the same is pursuant to Not Applicable change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after No comments review Comments of the auditors, if any No comments Objects for which funds have been raised and where there has been a deviation, in the following table Original Modified Original Modified Funds Amount Remark Object Object, if Allocation Allocation Utilized of s, if any any , if any Deviatio Variatio for the quarter accordin g to applicab le object Funding the Not 31,25,30,000 Not 6,84,00,000 No - working capital Applicable Applicable deviation requirements our Company Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Funding the Not 25,00,00,000 Not Nil No - product Applicable Applicable deviation development expenditure for the Company Investment in Not 15,00,00,000 Not 6,15,01,000 No - our Applicable Applicable deviation subsidiaries, by way of loan, to fund their working capital requirements General Not 23,75,10,000 Not 3,92,09,000 No - Corporate Applicable Applicable deviation Purpose Total 95,00,40,000 16,91,10,000 Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263